Patents Assigned to Dicerna Pharmaceuticals, Inc.
  • Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
    Patent number: 9809819
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing KRAS target RNA and protein levels via use of Dicer substrate siRNA (DsiRNA) agents possessing asymmetric end structures.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: November 7, 2017
    Assignee: DICERNA PHARMACEUTICALS, INC.
    Inventor: Bob D. Brown
  • THERAPEUTIC INHIBITION OF LACTATE DEHYDROGENASE AND AGENTS THEREFOR
    Publication number: 20170306332
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing lactate dehydrogenase target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Application
    Filed: October 9, 2015
    Publication date: October 26, 2017
    Applicant: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek, Cheng Lai
  • METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GLYCOLATE OXIDASE (HAO1) BY DOUBLE-STRANDED RNA
    Publication number: 20170306333
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Application
    Filed: June 7, 2017
    Publication date: October 26, 2017
    Applicant: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Phase changing formulations of nucleic acid payloads
    Patent number: 9790498
    Abstract: The present invention is based, at least in part, upon discovery of a process for identifying phase changing peptides. Such phase changing peptides are capable of enhancing in vitro and in vivo delivery of oligonucleotides (e.g., dsRNAs) in lipidic, vesicular, micellar and/or naked oligonucleotide formulations.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: October 17, 2017
    Assignee: DICERNA PHARMACEUTICALS, INC.
    Inventors: Bob Dale Brown, Sujit Kumar Basu
  • Methods and compositions for the specific inhibition of androgen receptor by double-stranded RNA
    Patent number: 9732347
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing AR target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: November 17, 2014
    Date of Patent: August 15, 2017
    Assignee: DICERNA PHARMACEUTICALS, INC
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Methods and compositions for the specific inhibition of MCL1 by double-stranded RNA
    Patent number: 9708605
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing MCL1 target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: July 18, 2017
    Assignee: DICERNA PHARMACEUTICALS, INC.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
    Patent number: 9701966
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: December 26, 2014
    Date of Patent: July 11, 2017
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Methods and compositions for the specific inhibition of met by double stranded RNA
    Patent number: 9670488
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing MET target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: June 6, 2017
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • RNAi PHARMACEUTICAL COMPOSITION FOR SUPPRESSING EXPRESSION OF CKAP5 GENE
    Publication number: 20170101639
    Abstract: The present invention provides a composition for suppressing the expression of the CKAP5 gene, the composition comprising a lipid particle containing a double-stranded nucleic acid as a drug and a cationic lipid, the double-stranded nucleic acid having an antisense strand having a base sequence complementary to the sequence of at least 19 continuous bases in CKAP5 gene mRNA of any one of SEQ ID NOs: 1 to 6, the cationic lipid being represented by formula (I): wherein R1 and R2 are the same or different and are each linear or branched alkyl, alkenyl or alkynyl of 12 to 24 carbon atoms; L1 and L2 are the same or different and are each —CO—O— or —O—CO—; a and b are the same or different and are each 1 to 3; and R3 is a hydrogen atom, alkyl of 1 to 6 carbon atoms, or alkenyl of 3 to 6 carbon atoms; a medicament comprising the composition, and the like.
    Type: Application
    Filed: June 4, 2015
    Publication date: April 13, 2017
    Applicants: Kyowa Hakko Kirin Co., Ltd., DICERNA PHARMACEUTICALS, INC.
    Inventors: Hayato YABUUCHI, Kana KURIHARA, Ayumi YAMADA, Keiko NAKAHASHI, Kentaro HATANAKA, Shiho TOMURA
  • Methods and compositions for the specific inhibition of MYC by double-stranded RNA
    Patent number: 9562228
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing MYC target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: February 7, 2017
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Amine cationic lipids and uses thereof
    Patent number: 9549983
    Abstract: The present invention relates to lipid compounds and uses thereof. In particular, the compounds include a class of cationic lipids having an amine moiety, such as an amino-amine or an amino-amide moiety. The lipid compounds are useful for in vivo or in vitro delivery of one or more agents (e.g., a polyanionic payload or an antisense payload, such as an RNAi agent).
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: January 24, 2017
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob Dale Brown, Sujit Kumar Basu, David A. Schwartz, Allister Fraser
  • Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
    Patent number: 9458457
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: October 4, 2016
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Methods and compositions for the specific inhibition of beta-catenin by double-stranded RNA
    Patent number: 9428752
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-catenin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: August 30, 2016
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Methods and compositions for the specific inhibition of MYC by double-stranded RNA
    Patent number: 9365850
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing MYC target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: June 14, 2016
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Lipid delivery formulations
    Patent number: 9320798
    Abstract: The invention provides formulations that contain an immunogenic or immunostimulatory cargo, delivery moiety and/or lipid, and a lipid that functions to reduce or prevent induction in a subject of an immune response which would otherwise occur when the immunogenic or immunostimulatory cargo, delivery moiety and/or lipid is administered to a subject as a component of an appropriate control formulation lacking the immune response reducing lipid. Specific immune response reducing lipids and uses thereof are further provided.
    Type: Grant
    Filed: August 27, 2012
    Date of Patent: April 26, 2016
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventor: Bob D. Brown
  • Methods and compositions for the specific inhibition of beta-catenin by double stranded RNA
    Patent number: 9243244
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-catenin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: June 10, 2014
    Date of Patent: January 26, 2016
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Phase changing formulations of nucleic acid payloads
    Patent number: 9217146
    Abstract: The present invention is based, at least in part, upon discovery of a process for identifying phase changing peptides. Such phase changing peptides are capable of enhancing in vitro and in vivo delivery of oligonucleotides (e.g., dsRNAs) in lipidic, vesicular, micellar and/or naked oligonucleotide formulations.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: December 22, 2015
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob Dale Brown, Sujit Kumar Basu
  • Methods and compositions for the specific inhibition of HIF-1? by double-stranded RNA
    Patent number: 9206420
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing HIF-1? target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: December 8, 2015
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob Dale Brown, Henryk T. Dudek
  • Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
    Patent number: 9200284
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing KRAS target RNA and protein levels via use of Dicer substrate siRNA (DsiRNA) agents possessing asymmetric end structures.
    Type: Grant
    Filed: January 10, 2013
    Date of Patent: December 1, 2015
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventor: Bob D. Brown
  • METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF CKAP5 BY DOUBLE-STRANDED RNA
    Publication number: 20150315583
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing CKAP5 target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Application
    Filed: December 13, 2013
    Publication date: November 5, 2015
    Applicant: DICERNA PHARMACEUTICALS, INC.
    Inventors: Bob D. Brown, Henryk T. Dudek